HK1088234A1 - Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders - Google Patents
Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disordersInfo
- Publication number
- HK1088234A1 HK1088234A1 HK06108608.1A HK06108608A HK1088234A1 HK 1088234 A1 HK1088234 A1 HK 1088234A1 HK 06108608 A HK06108608 A HK 06108608A HK 1088234 A1 HK1088234 A1 HK 1088234A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- disorders
- treatment
- inflammatory diseases
- oxidized lipids
- lipids
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title 2
- 150000002632 lipids Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/04—Saturated ethers
- C07C43/13—Saturated ethers containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
- C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
- C07C43/1787—Unsaturated ethers containing hydroxy or O-metal groups containing six-membered aromatic rings and having unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/445,347 US6838452B2 (en) | 2000-11-24 | 2003-05-27 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
PCT/IL2004/000453 WO2004106486A2 (fr) | 2003-05-27 | 2004-05-27 | Lipides oxydes et leur utilisation dans le traitement de maladies et de troubles inflammatoires |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1088234A1 true HK1088234A1 (en) | 2006-11-03 |
Family
ID=33489370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06108608.1A HK1088234A1 (en) | 2003-05-27 | 2006-08-03 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders |
Country Status (17)
Country | Link |
---|---|
US (10) | US6838452B2 (fr) |
EP (1) | EP1626728B1 (fr) |
JP (2) | JP5255209B2 (fr) |
KR (2) | KR101122160B1 (fr) |
CN (2) | CN102040621B (fr) |
AU (1) | AU2004243695B2 (fr) |
CA (1) | CA2527483A1 (fr) |
DK (1) | DK1626728T3 (fr) |
ES (1) | ES2429134T3 (fr) |
HK (1) | HK1088234A1 (fr) |
IL (1) | IL172165A (fr) |
MX (1) | MXPA05012784A (fr) |
NZ (1) | NZ544285A (fr) |
PT (1) | PT1626728E (fr) |
RU (3) | RU2362567C2 (fr) |
WO (1) | WO2004106486A2 (fr) |
ZA (1) | ZA200509929B (fr) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7052686B2 (en) | 2000-09-29 | 2006-05-30 | Schering Corporation | Pegylated interleukin-10 |
US8071740B2 (en) * | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
AU2003222427B8 (en) * | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
US20050119301A1 (en) * | 2001-03-16 | 2005-06-02 | Alan Husband | Treatment of restenosis |
DE60237777D1 (de) | 2001-10-19 | 2010-11-04 | Vascular Biogenics Ltd | Etzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie |
US8012483B2 (en) | 2004-04-15 | 2011-09-06 | Athera Biotechnologies Ab | Phosphorylcholine conjugates and corresponding antibodies |
US7807847B2 (en) * | 2004-07-09 | 2010-10-05 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
CN101039680B (zh) * | 2004-07-09 | 2011-08-03 | 脉管生物生长有限公司 | 制备氧化磷脂的改进方法 |
AU2007200090B2 (en) * | 2004-07-09 | 2011-09-22 | Vascular Biogenics Ltd. | Improved Process for the Preparation of Oxidized Phospholipids |
US7183215B2 (en) * | 2004-07-21 | 2007-02-27 | Hewlett-Packard Development Company, L.P. | Etching with electrostatically attracted ions |
WO2006109170A2 (fr) * | 2005-04-14 | 2006-10-19 | Esperion Therapeutics Inc. | Polytherapie destinee au traitement de maladies cardiovasculaires et de pathologies associees |
KR20080073288A (ko) * | 2005-12-09 | 2008-08-08 | 드러그테크 코포레이션 | 정맥내 필수 지방산 에멀젼 |
US8961982B2 (en) * | 2005-12-16 | 2015-02-24 | The Regents Of The University Of California | Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer |
WO2007137864A1 (fr) * | 2006-06-01 | 2007-12-06 | Eucro European Contract Research Gmbh & Co. Kg | Utilisation d'inhibiteurs du pp2c pour traiter ou prévenir l'artériosclérose |
US9308198B2 (en) | 2006-09-08 | 2016-04-12 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced brain disease |
US20080081031A1 (en) | 2006-09-28 | 2008-04-03 | Schering Corporation | Use of Pegylated IL-10 to Treat Cancer |
US9006217B2 (en) * | 2007-01-09 | 2015-04-14 | Vascular Biogenics Ltd. | High-purity phospholipids |
US8569529B2 (en) * | 2007-01-09 | 2013-10-29 | Vascular Biogenics Ltd. | High-purity phospholipids |
EP2620147B1 (fr) | 2007-02-08 | 2020-06-03 | Med-Life Discoveries LP | Composés pour abaisser le cholestérol |
US20100261682A1 (en) * | 2007-09-17 | 2010-10-14 | Bioneris Ab | Method and Means for the Treatment of Cachexia |
WO2009050692A2 (fr) * | 2007-10-16 | 2009-04-23 | Vascular Biogenics Ltd. | Analogues du facteur d'activation des plaquettes (paf) et ses utilisations |
MX2010004885A (es) * | 2007-10-30 | 2010-08-04 | Athera Biotechnologies Ab | Diagnostico y metodos terapeuticos y composiciones para enfermedades cardiovasculares. |
US7993666B2 (en) * | 2008-04-18 | 2011-08-09 | Warsaw Orthopedic, Inc. | Methods and compositions for treating pain comprising a statin |
EP2127639A1 (fr) * | 2008-05-26 | 2009-12-02 | Universiteit Utrecht Holding B.V. | Liposomes contenant des corticostéroïdes pour le traitement des maladies cardiovasculaires |
US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
KR101729340B1 (ko) * | 2008-08-12 | 2017-04-24 | 진판델 파마슈티컬스 인코포레이티드 | 질환 위험 인자의 식별 방법 |
WO2010041242A2 (fr) * | 2008-10-08 | 2010-04-15 | Vascular Biogenics Ltd. | Composés de thiophospholipides oxydés et leurs utilisations |
EP2826369A3 (fr) * | 2008-11-06 | 2015-03-18 | Vascular Biogenics Ltd. | Composés lipidiques oxydés et leurs utilisations |
TWI475989B (zh) * | 2008-12-22 | 2015-03-11 | Phenomenome Discoveries Inc | 縮醛磷脂類化合物,含彼之醫藥組成物以及治療老化疾病的方法 |
DE102009007853A1 (de) * | 2009-02-06 | 2010-08-12 | LMU Ludwig-Maximilians-Universität München | Mit Alkylphosphocholinen behandelte Intraokularlinsen zur pharmakologischen Nachstarprophylaxe |
BRPI1010639A2 (pt) * | 2009-05-13 | 2016-03-15 | Protein Delivery Solutions Llc | sistema farmacêutico para distribuição transmembrana |
AU2011204406B2 (en) * | 2010-01-05 | 2015-05-07 | Vascular Biogenics Ltd. | Treatment with VB-201 |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
US9102666B2 (en) | 2011-01-10 | 2015-08-11 | Zinfandel Pharmaceuticals, Inc. | Methods and drug products for treating Alzheimer's disease |
US9222948B2 (en) * | 2011-06-01 | 2015-12-29 | Wake Forest University Health Sciences | Methods of measuring amount of cholesteryl ester in a blood sample |
DE102011103948A1 (de) * | 2011-06-06 | 2012-12-06 | B. Braun Melsungen Ag | Biopassivierende Beschichtung von Gefäßprothesen mit Nitrocarbonsäuren enthaltenden Phospholipiden |
WO2012170417A2 (fr) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Procédés et compositions pour améliorer la croissance osseuse comprenant une statine |
US9796786B2 (en) | 2011-08-09 | 2017-10-24 | Athera Biotechnologies Ab | Antibodies binding to phosphorylcholine (PC) and/or PC conjugates |
EP2742068B1 (fr) | 2011-08-09 | 2019-04-03 | Athera Biotechnologies AB | Nouveaux anticorps contre la phosphorylcholine |
EA029274B1 (ru) * | 2011-09-01 | 2018-03-30 | Васкьюлар Байодженикс Лтд. | Препараты и лекарственные формы на основе окисленных фосфолипидов |
US9006305B2 (en) | 2011-09-01 | 2015-04-14 | Vertellus Specialties Inc. | Biocompatible material |
US8980956B2 (en) | 2011-09-01 | 2015-03-17 | Vertellus Specialities Inc. | Methods for producing biocompatible materials |
GB201119363D0 (en) | 2011-11-10 | 2011-12-21 | Vertellus Specialities Inc | Polymerisable material |
CA2858789C (fr) * | 2011-12-12 | 2020-09-22 | Vascular Biogenics Ltd. | Traitement de l'inflammation |
WO2013121300A2 (fr) * | 2012-02-16 | 2013-08-22 | Vascular Biogenics Ltd. | Procédés de traitement du psoriasis et de l'inflammation vasculaire |
WO2014160305A1 (fr) * | 2013-03-14 | 2014-10-02 | Albany Molecular Research, Inc. | Conjugués ligand-agent thérapeutiques et lieurs à base de silicium |
BR112015026122A8 (pt) * | 2013-04-18 | 2020-01-21 | Armo Biosciences Inc | agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit |
US9823255B2 (en) | 2013-06-17 | 2017-11-21 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
US10010588B2 (en) | 2013-08-30 | 2018-07-03 | Armo Biosciences, Inc. | Methods of using pegylated interleukin-10 for treating hyperlipidemia |
KR101639128B1 (ko) * | 2013-10-29 | 2016-07-13 | 울산대학교 산학협력단 | 플라스마로젠 전구체, 플라스마로젠 또는 플라스마로젠 유사체를 유효성분으로 함유하는 간질환 예방 또는 치료용 약학조성물 |
WO2015064960A1 (fr) * | 2013-10-29 | 2015-05-07 | 울산대학교 산학협력단 | Composition pharmaceutique servant à la prévention ou au traitement de maladies hépatiques contenant comme constituant efficace un précurseur de plasmalogène, un plasmalogène ou un analogue de plasmalogène |
US11413332B2 (en) | 2013-11-11 | 2022-08-16 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
US10293043B2 (en) | 2014-06-02 | 2019-05-21 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
WO2016041013A1 (fr) * | 2014-09-16 | 2016-03-24 | Baker Idi Heart And Diabetes Institute Holdings Limited | Glycérolipides et leurs utilisations |
WO2016060996A2 (fr) | 2014-10-14 | 2016-04-21 | Armo Biosciences, Inc. | Compositions d'interleukine-15 et leurs utilisations |
WO2016064817A1 (fr) | 2014-10-22 | 2016-04-28 | Armo Biosciences, Inc. | Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles |
US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
JP6717825B2 (ja) | 2014-11-26 | 2020-07-08 | バスキュラー バイオジェニックス リミテッド | 酸化脂質、および線維症の処置または予防方法 |
US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
AU2016268403A1 (en) | 2015-05-28 | 2017-12-07 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
EP3341012A4 (fr) | 2015-08-25 | 2019-03-20 | Armo Biosciences, Inc. | Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles |
RU2635665C1 (ru) * | 2017-02-16 | 2017-11-15 | Общество с ограниченной ответственностью "БИОН" | Способ получения l-a-глицерофосфорилхолина фармакопейного качества |
KR101983298B1 (ko) * | 2018-06-11 | 2019-05-29 | 연세대학교 산학협력단 | 인플라마좀 매개 염증성 질환의 예방 또는 치료용 약학 조성물 |
CN108864187B (zh) * | 2018-08-06 | 2020-12-25 | 兰博尔开封科技有限公司 | 一种合成氧乐果重要中间体氧硫磷酯的工艺 |
MX2021009328A (es) * | 2019-02-21 | 2021-11-12 | Univ Claude Bernard Lyon | Vectores moleculares estructurados y usos de los mismos. |
NL2025022B1 (en) * | 2020-02-28 | 2021-10-14 | Acad Medisch Ct | Intervention strategy for prevention or treatment of autoimmune diseases |
JP6859562B1 (ja) * | 2020-03-31 | 2021-04-14 | 株式会社 レオロジー機能食品研究所 | 脂肪肝改善用組成物 |
US11491130B2 (en) | 2021-02-05 | 2022-11-08 | Retrotope, Inc. | Methods of treating amyotrophic lateral sclerosis |
KR20240064584A (ko) * | 2021-02-05 | 2024-05-13 | 레트로토프 인코포레이티드 | 중수소화 아라키돈산을 사용한 신경퇴행성 질환의 치료에 대한 환자의 반응을 평가하는 방법 |
JPWO2023089986A1 (fr) * | 2021-11-22 | 2023-05-25 | ||
WO2024086663A1 (fr) * | 2022-10-19 | 2024-04-25 | Corner Therapeutics, Inc. | Lipides d'ether pour l'hyperactivation de cellules dendritiques de mammifères |
WO2024148052A1 (fr) * | 2023-01-03 | 2024-07-11 | Baker Heart and Diabetes Institute | Éther de phosphatidylcholine et de phosphatidyléthanolamine, leurs formes lyso et leur mélange pour une utilisation dans le traitement d'une maladie ou d'un trouble provoqué par une déficience en plasmalogènes |
Family Cites Families (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1572226A (en) | 1977-11-03 | 1980-07-30 | Hoechst Uk Ltd | Pharmaceutical preparations in solid unit dosage form |
CH642665A5 (en) | 1979-02-08 | 1984-04-30 | Rudolf Berchtold | Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides |
US4329302A (en) | 1980-06-27 | 1982-05-11 | Board Of Regents, The University Of Texas System | Synthetic phosphoglycerides possessing platelet activating properties |
US4410237A (en) | 1980-09-26 | 1983-10-18 | Massachusetts Institute Of Technology | Method and apparatus for shaping electromagnetic beams |
DE3307925A1 (de) | 1983-03-05 | 1984-09-06 | A. Nattermann & Cie GmbH, 5000 Köln | Neue 0-acyl-alkandiol-phospholipide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
US4614796A (en) | 1983-03-25 | 1986-09-30 | Nippon Shinyaku Co., Ltd. | Liposome and method of manufacture therefor |
JPS60100544A (ja) | 1983-11-08 | 1985-06-04 | Ono Pharmaceut Co Ltd | 新規なグリセリン誘導体,その製造方法及びその誘導体を含有する薬剤 |
JPS60104066A (ja) | 1983-11-10 | 1985-06-08 | Ono Pharmaceut Co Ltd | グリセリン誘導体 |
AT383130B (de) | 1984-05-15 | 1987-05-25 | Chemie Linz Ag | Verfahren zur herstellung von an c1 und c2 verschieden substituierten phosphatidylcholinen und phosphatidylethanolaminen ueber die neuen verbindungen 1-0-tritylglycerophosphocholin beziehungsweise (1-0,n-ditrityl)-glycerophosphoethanolamin |
JPS6168494A (ja) * | 1984-09-11 | 1986-04-08 | Kao Corp | 燐脂質誘導体およびそれを含有する消炎鎮痛剤 |
US4710579A (en) | 1984-11-09 | 1987-12-01 | Takeda Chemical Industries, Ltd. | 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof |
JPH0617307B2 (ja) * | 1984-11-09 | 1994-03-09 | 武田薬品工業株式会社 | 抗腫瘍剤 |
US4827011A (en) | 1984-12-10 | 1989-05-02 | American Cyanamid Company | Antihypertensive phosphate derivatives |
ATE171185T1 (de) | 1985-03-15 | 1998-10-15 | Antivirals Inc | Immunotestmittel für polynukleotid und verfahren |
US4711512A (en) | 1985-07-12 | 1987-12-08 | Environmental Research Institute Of Michigan | Compact head-up display |
EP0225129B1 (fr) | 1985-11-29 | 1989-05-24 | Takeda Chemical Industries, Ltd. | Dérivés phospholipidiques, leur préparation et leur utilisation |
EP0299965A4 (en) | 1986-03-24 | 1992-12-16 | University Of Sydney | Antigenic analogues of platelet activating factor (paf) |
EP0299972B1 (fr) | 1986-04-07 | 1992-03-04 | The Upjohn Company | Acylhydrazones d'alkyle quaternaire anthelmintiques, procede d'utilisation et compositions |
JPS6294A (ja) * | 1986-05-09 | 1987-01-06 | Toyama Chem Co Ltd | 新規なグリセロリン酸誘導体およびその塩並びにそれらの製造法 |
JPS6354386A (ja) | 1986-08-26 | 1988-03-08 | Takeda Chem Ind Ltd | リン脂質およびその用途 |
JPS63135395A (ja) | 1986-11-28 | 1988-06-07 | Nippon Oil & Fats Co Ltd | リン脂質誘導体及びその製造方法 |
US4866042A (en) * | 1987-11-18 | 1989-09-12 | Neuwelt Edward A | Method for the delivery of genetic material across the blood brain barrier |
DE3807123A1 (de) | 1988-03-04 | 1989-09-14 | Boehringer Mannheim Gmbh | Substrate fuer phospholipasen |
JPH01258691A (ja) * | 1988-04-06 | 1989-10-16 | Nippon Oil & Fats Co Ltd | リン脂質誘導体及びその製造方法 |
JP2534894B2 (ja) | 1988-06-24 | 1996-09-18 | 日本ケミファ株式会社 | 新規なグリセリン誘導体およびその誘導体を含有する血圧降下剤 |
JPH0248585A (ja) * | 1988-08-10 | 1990-02-19 | Nippon Oil & Fats Co Ltd | リン脂質誘導体及びその製造方法 |
US5464764A (en) * | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
US6337209B1 (en) * | 1992-02-26 | 2002-01-08 | Glaxo Wellcome Inc. | Molecular constructs containing a carcinoembryonic antigen regulatory sequence |
US5237451A (en) | 1989-11-17 | 1993-08-17 | Minnesota Mining And Manufacturing Company | Beam shaping system using diffraction |
US5082629A (en) | 1989-12-29 | 1992-01-21 | The Board Of The University Of Washington | Thin-film spectroscopic sensor |
JPH03258740A (ja) | 1990-03-06 | 1991-11-19 | Kao Corp | 液体油、その製造法及びこれを含有する化粧料 |
ES2019552A6 (es) * | 1990-04-11 | 1991-06-16 | Menarini Lab | Procedimiento para la preparacion de glicerofosfolipidos. |
JP2869572B2 (ja) | 1990-05-14 | 1999-03-10 | 和光純薬工業株式会社 | ホスファチジルコリン誘導体の製造方法 |
JPH0497201A (ja) | 1990-08-10 | 1992-03-30 | Matsushita Electric Ind Co Ltd | ビームエキスパンド装置および回折格子の製造方法 |
WO1992015680A1 (fr) * | 1991-03-06 | 1992-09-17 | Board Of Regents, The University Of Texas System | Procedes et compositions d'inhibition selective de l'expression de genes |
US5224198A (en) | 1991-09-30 | 1993-06-29 | Motorola, Inc. | Waveguide virtual image display |
US5561052A (en) | 1992-06-18 | 1996-10-01 | Koike; Katsumasa | Process for detecting oxidized lipids and process for forming oxidized lipids |
JPH06230225A (ja) | 1993-02-03 | 1994-08-19 | Nissan Motor Co Ltd | 表示装置 |
JPH06250022A (ja) | 1993-02-26 | 1994-09-09 | Nissan Motor Co Ltd | 表示装置 |
JP3623250B2 (ja) | 1993-06-23 | 2005-02-23 | オリンパス株式会社 | 映像表示装置 |
US5635385A (en) * | 1993-09-15 | 1997-06-03 | Temple University-Of The Commonwealth System Of Higher Education | Multi-unit ribozyme inhibition of oncogene gene expression |
EP0724743A1 (fr) | 1993-10-22 | 1996-08-07 | Kopin Corporation | Systeme de visualisation monte au niveau de la tete |
DE4440819A1 (de) * | 1993-11-19 | 1995-05-24 | Ciba Geigy Ag | Photoempfindliche Zusammensetzungen |
FR2714382B1 (fr) | 1993-12-27 | 1996-02-02 | Roussel Uclaf | Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques. |
JPH07224076A (ja) * | 1994-02-10 | 1995-08-22 | Sagami Chem Res Center | ホスホリパーゼa2の阻害剤 |
WO1995023592A1 (fr) | 1994-03-04 | 1995-09-08 | The University Of British Columbia | Compositions a base de liposomes et procedes de traitement de l'atherosclerose |
US6037329A (en) * | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
JP3364313B2 (ja) | 1994-03-22 | 2003-01-08 | 株式会社トクヤマ | ポルフィリン/インジウム錯体及び陰イオン感応膜 |
US6579697B1 (en) * | 1995-05-11 | 2003-06-17 | Yeda Research And Development Co. Ltd. | Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors |
JPH07326065A (ja) | 1994-05-27 | 1995-12-12 | Hitachi Ltd | 光情報処理装置 |
US8715645B2 (en) * | 1994-05-27 | 2014-05-06 | The Regents Of The University Of Colorado | Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same |
US5747340A (en) | 1994-06-03 | 1998-05-05 | Syntex (U.S.A.) Inc. | Targeted gene expression using preproendothelin-1 promoters |
US5906827A (en) * | 1994-06-03 | 1999-05-25 | Creative Biomolecules, Inc. | Matrix for the manufacture of autogenous replacement body parts |
GB9506466D0 (en) * | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
DE69535758D1 (de) * | 1994-08-29 | 2008-07-03 | Univ Wake Forest | Lipid-analoge zur behandlung von viralen infektionen |
US5734039A (en) * | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
US5506929A (en) | 1994-10-19 | 1996-04-09 | Clio Technologies, Inc. | Light expanding system for producing a linear or planar light beam from a point-like light source |
JPH08208548A (ja) | 1995-02-01 | 1996-08-13 | Kao Corp | グリセリン誘導体の製造法 |
US5712149A (en) * | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
US5660855A (en) | 1995-02-10 | 1997-08-26 | California Institute Of Technology | Lipid constructs for targeting to vascular smooth muscle tissue |
US5792453A (en) * | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
US6261597B1 (en) | 1995-08-31 | 2001-07-17 | Seymour J. Kurtz | Method for treating periodontal disease |
US5916763A (en) * | 1995-11-09 | 1999-06-29 | The Regents Of The University Of California | Promoter for VEGF receptor |
US6825980B2 (en) | 1995-12-18 | 2004-11-30 | Metrologic Instruments, Inc. | DOE-based systems and devices for producing laser beams having modified beam characteristics |
CA2270160A1 (fr) * | 1996-11-08 | 1998-05-14 | Oklahoma Medical Research Foundation | Expression specifique de l'endothelium regulee par des elements regulateurs du recepteur epcr |
US6096291A (en) | 1996-12-27 | 2000-08-01 | Biovector Therapeutics, S.A. | Mucosal administration of substances to mammals |
AU741439B2 (en) * | 1996-12-30 | 2001-11-29 | Battelle Memorial Institute | Formulation and method for treating neoplasms by inhalation |
US6206917B1 (en) * | 1997-05-02 | 2001-03-27 | St. Jude Medical, Inc. | Differential treatment of prosthetic devices |
WO1999006563A1 (fr) * | 1997-07-30 | 1999-02-11 | Emory University | Nouvelle proteine de mineralisation osseuse, adn, vecteurs et systemes d'expressions |
US6204055B1 (en) * | 1999-04-12 | 2001-03-20 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Fas mediated signaling |
JP3781877B2 (ja) * | 1997-10-03 | 2006-05-31 | 株式会社ムック | アスコルビン酸誘導体またはその塩、および医薬 |
EP0909532A1 (fr) * | 1997-10-16 | 1999-04-21 | Development Center For Biotechnology | Matériau poreux et compatible avec l'environnement contenant des nématodes benefiques et sa préparation |
EP1030676B1 (fr) * | 1997-10-30 | 2005-09-14 | The General Hospital Corporation | Assemblage de matrices cartilagineuses au moyen de chondrocytes isoles |
DE69912759T2 (de) | 1998-04-02 | 2004-09-30 | Elop Electro-Optics Industries Ltd. | Optische holographische Vorrichtung |
CA2331844A1 (fr) * | 1998-05-07 | 1999-11-11 | University Of Maryland, Baltimore | Methode de diagnostic et de traitement du syndrome de douleur pelvienne chronique |
US6239151B1 (en) * | 1998-06-26 | 2001-05-29 | Hoffmann-La Roche Inc. | Compounds as inhibitor of tumor necrosis factor alpha release |
DE19838837A1 (de) | 1998-08-27 | 2000-03-02 | Boehringer Ingelheim Int | Zellspezifische Promoter des Entkopplungsproteins 3 |
US20020164434A1 (en) | 1998-09-29 | 2002-11-07 | Michael Tarvin | Ultra violet light curable floor coating with coloring agent |
CA2356736A1 (fr) * | 1998-12-21 | 2000-06-29 | Inkeysa. S.A. | Utilisation d'etherlysophospholipides en tant qu'agents anti-inflammatoires |
US6414168B1 (en) | 1998-12-28 | 2002-07-02 | Caschem, Inc. | Epoxidation of ricinic compounds using a phase-transfer catalyst |
JP3622556B2 (ja) | 1999-02-23 | 2005-02-23 | セイコーエプソン株式会社 | 照明光学系および投写型表示装置 |
IL130608A0 (en) * | 1999-06-23 | 2000-06-01 | Compugen Ltd | Novel nucleic and amino acid sequence |
US6545048B1 (en) * | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
US6348583B1 (en) * | 1999-08-30 | 2002-02-19 | Bio-Rad Laboratories, Inc. | Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids |
AU1226001A (en) * | 1999-11-09 | 2001-06-06 | Alcon Universal Limited | Phospholipids of hydroxyeicosatetraenoic acid-like derivatives |
ATE287700T1 (de) * | 1999-11-30 | 2005-02-15 | Univ Arizona | Strahlung-sensitive liposomen |
US6576265B1 (en) * | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
US6376244B1 (en) * | 1999-12-29 | 2002-04-23 | Children's Medical Center Corporation | Methods and compositions for organ decellularization |
US6479064B1 (en) * | 1999-12-29 | 2002-11-12 | Children's Medical Center Corporation | Culturing different cell populations on a decellularized natural biostructure for organ reconstruction |
US6687360B2 (en) * | 1999-12-30 | 2004-02-03 | At&T Corp. | Personal IP follow-me service |
TWI238183B (en) * | 2000-01-12 | 2005-08-21 | Sumitomo Chemical Co | Polymeric fluorescent substance and polymer light-emitting device |
US6265216B1 (en) * | 2000-01-20 | 2001-07-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of cot oncogene expression |
US6866864B2 (en) * | 2000-03-20 | 2005-03-15 | Ahmed Mousa | Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders |
DK1272666T3 (da) * | 2000-03-31 | 2006-02-27 | Univ California | Et funktionsassay for höjdensitetslipoprotein |
US6652583B2 (en) * | 2000-04-07 | 2003-11-25 | Rhode Island Hospital | Cardiac valve replacement |
JP2002122783A (ja) | 2000-10-13 | 2002-04-26 | Olympus Optical Co Ltd | 観察光学系及び撮像光学系及びそれを用いた装置 |
EP1328565B1 (fr) | 2000-10-25 | 2005-09-28 | Akzo Nobel Coatings International B.V. | Composition de revetement aqueux photoactivable |
US20070286845A1 (en) * | 2000-11-17 | 2007-12-13 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
US8039261B2 (en) * | 2000-11-17 | 2011-10-18 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
MXPA03004325A (es) * | 2000-11-17 | 2004-01-26 | Vascular Biogenics Ltd | Promotores que muestran especificidad celular endotelial y metodos para su uso. |
AU2003222427B8 (en) * | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
US20100282634A1 (en) * | 2000-11-17 | 2010-11-11 | Dror Harats | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
US8071740B2 (en) * | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
US7067649B2 (en) * | 2000-11-17 | 2006-06-27 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
IL156015A0 (en) * | 2000-11-24 | 2003-12-23 | Vascular Biogenics Ltd | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
US7034131B2 (en) | 2001-01-29 | 2006-04-25 | Bio-Rad Laboratories Inc. | Nucleic acid derivatives |
US6458588B1 (en) | 2001-01-31 | 2002-10-01 | The General Hospital Corporation | Renal stem cells and uses thereof |
KR20020083737A (ko) | 2001-04-30 | 2002-11-04 | 삼성전자 주식회사 | 착용형 디스플레이 시스템 |
US6438802B1 (en) * | 2001-06-07 | 2002-08-27 | Randolph Scott Beeman | Locking mechanism and method for securely fastening resilient cords and tubing |
KR100453877B1 (ko) * | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
JP2005503378A (ja) | 2001-08-06 | 2005-02-03 | ジエノメツド・エル・エル・シー | Aceの過剰に関連する疾患の治療方法及び組成物 |
US6833955B2 (en) | 2001-10-09 | 2004-12-21 | Planop Planar Optics Ltd. | Compact two-plane optical device |
DE60237777D1 (de) * | 2001-10-19 | 2010-11-04 | Vascular Biogenics Ltd | Etzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie |
DE10155095A1 (de) | 2001-11-09 | 2003-05-22 | Cognis Deutschland Gmbh | Alkyl(en)ylglycerinethercarbonsäuren |
KR100450815B1 (ko) | 2002-02-01 | 2004-10-01 | 삼성전자주식회사 | 조명계 및 이를 채용한 프로젝션 디스플레이 장치 |
US6757105B2 (en) | 2002-04-25 | 2004-06-29 | Planop Planar Optics Ltd. | Optical device having a wide field-of-view for multicolor images |
US7023622B2 (en) | 2002-08-06 | 2006-04-04 | Dmetrix, Inc. | Miniature microscope objective lens |
US6805490B2 (en) | 2002-09-30 | 2004-10-19 | Nokia Corporation | Method and system for beam expansion in a display device |
EP1577872A4 (fr) | 2002-12-26 | 2008-11-26 | Sanyo Electric Co | Dispositif de presentation video du type a projection |
JP2005050666A (ja) | 2003-07-28 | 2005-02-24 | Tokai Rubber Ind Ltd | 燃料電池用ホース材料およびそれを用いてなる燃料電池用ホース |
CA2536909A1 (fr) | 2003-08-29 | 2005-03-10 | Regents Of The University Of Minnesota | Cellules souches renales et methodes d'isolement, de differenciation et d'utilisation des cellules souches |
US7184617B2 (en) | 2004-03-12 | 2007-02-27 | Matsushita Electric Industrial Co., Ltd. | Portable device |
US7123693B2 (en) * | 2004-03-13 | 2006-10-17 | Intrado Inc. | Method and apparatus for increasing the reliability of an emergency call communication network |
US7177398B2 (en) * | 2004-03-13 | 2007-02-13 | Intrado Inc. | Bi-directional messaging for an emergency services network |
CN101039680B (zh) | 2004-07-09 | 2011-08-03 | 脉管生物生长有限公司 | 制备氧化磷脂的改进方法 |
US7807847B2 (en) | 2004-07-09 | 2010-10-05 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
CA2575163A1 (fr) * | 2004-08-09 | 2006-02-23 | Merck & Co., Inc. | Compositions de vecteurs adenoviraux |
KR101157230B1 (ko) * | 2004-08-17 | 2012-06-15 | 삼성코닝정밀소재 주식회사 | 나노 기공을 포함하는 물질을 형성하기 위한 조성물 |
US20060056028A1 (en) | 2004-09-13 | 2006-03-16 | Wildnauer Kenneth R | Apodized diffraction grating with improved dynamic range |
US20060194765A1 (en) | 2004-11-16 | 2006-08-31 | Garcia Joe G N | Methods and compositions using oxidized phospholipids |
US7206107B2 (en) | 2004-12-13 | 2007-04-17 | Nokia Corporation | Method and system for beam expansion in a display device |
CA2596537A1 (fr) * | 2005-01-28 | 2006-08-03 | Apollo Life Sciences Limited | Molecules et leurs molecules chimeriques |
US8252775B2 (en) | 2005-07-21 | 2012-08-28 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating multiple sclerosis with phosphocholine containing lipids |
WO2007027905A2 (fr) | 2005-08-31 | 2007-03-08 | Science And Technology Corporation @ Unm | Cellules souches renales humaines |
WO2007031991A2 (fr) | 2005-09-14 | 2007-03-22 | Mirage Innovations Ltd. | Dispositif optique a diffraction et systeme |
US20080043334A1 (en) | 2006-08-18 | 2008-02-21 | Mirage Innovations Ltd. | Diffractive optical relay and method for manufacturing the same |
EP1764095A1 (fr) | 2005-09-20 | 2007-03-21 | Revotar Biopharmaceuticals AG | Nouveaux derivés de nitrocatéchol ayant activité de ligande de selectine |
EP1943556B1 (fr) | 2005-11-03 | 2009-02-11 | Mirage Innovations Ltd. | Dispositif de relais optique binoculaire |
US8137977B2 (en) * | 2006-04-24 | 2012-03-20 | Children's Hospital & Research Center At Oakland | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
US8703179B2 (en) | 2006-05-11 | 2014-04-22 | Kimberly-Clark Worldwide, Inc. | Mucosal formulation |
WO2007138576A1 (fr) | 2006-05-25 | 2007-12-06 | Mirage Innovations Ltd. | systÈme d'Éclairage avec intÉgrateur optique pour projecteur d'image |
JP2008037763A (ja) | 2006-08-01 | 2008-02-21 | Adeka Corp | 抗菌剤及び抗菌剤組成物 |
US8569529B2 (en) | 2007-01-09 | 2013-10-29 | Vascular Biogenics Ltd. | High-purity phospholipids |
KR20090011223A (ko) | 2007-07-25 | 2009-02-02 | 삼성전자주식회사 | 방송처리장치 및 그 제어방법 |
WO2009070298A1 (fr) * | 2007-11-28 | 2009-06-04 | Teva Pharmaceutical Industries, Ltd. | Procédé pour retarder le début d'une sclérose en plaques cliniquement définie |
WO2010041242A2 (fr) | 2008-10-08 | 2010-04-15 | Vascular Biogenics Ltd. | Composés de thiophospholipides oxydés et leurs utilisations |
EP2826369A3 (fr) | 2008-11-06 | 2015-03-18 | Vascular Biogenics Ltd. | Composés lipidiques oxydés et leurs utilisations |
US20110083464A1 (en) * | 2009-10-12 | 2011-04-14 | Craig Kettles | Refrigerator with a Pullout Refrigerator Compartment |
AU2011204406B2 (en) | 2010-01-05 | 2015-05-07 | Vascular Biogenics Ltd. | Treatment with VB-201 |
CA2786374C (fr) | 2010-01-05 | 2019-01-22 | Vascular Biogenics Ltd. | Procedes pour l'utilisation d'un agent adenoviral antiangiogenese specifique |
KR101810257B1 (ko) | 2010-01-05 | 2017-12-18 | 바스큘라 바이오제닉스 리미티드 | 아교모세포종 gbm을 치료하기 위한 조성물 및 방법 |
EA029274B1 (ru) | 2011-09-01 | 2018-03-30 | Васкьюлар Байодженикс Лтд. | Препараты и лекарственные формы на основе окисленных фосфолипидов |
-
2003
- 2003-05-27 US US10/445,347 patent/US6838452B2/en not_active Expired - Lifetime
- 2003-11-24 US US10/718,596 patent/US7186704B2/en not_active Expired - Lifetime
-
2004
- 2004-05-27 PT PT47350889T patent/PT1626728E/pt unknown
- 2004-05-27 CN CN201010537971.1A patent/CN102040621B/zh not_active Expired - Fee Related
- 2004-05-27 NZ NZ544285A patent/NZ544285A/en not_active IP Right Cessation
- 2004-05-27 RU RU2005140666/04A patent/RU2362567C2/ru not_active IP Right Cessation
- 2004-05-27 EP EP04735088.9A patent/EP1626728B1/fr not_active Expired - Lifetime
- 2004-05-27 DK DK04735088.9T patent/DK1626728T3/da active
- 2004-05-27 JP JP2006531006A patent/JP5255209B2/ja not_active Expired - Fee Related
- 2004-05-27 AU AU2004243695A patent/AU2004243695B2/en not_active Ceased
- 2004-05-27 US US10/567,543 patent/US7902176B2/en not_active Expired - Fee Related
- 2004-05-27 MX MXPA05012784A patent/MXPA05012784A/es active IP Right Grant
- 2004-05-27 CA CA002527483A patent/CA2527483A1/fr not_active Abandoned
- 2004-05-27 ES ES04735088T patent/ES2429134T3/es not_active Expired - Lifetime
- 2004-05-27 WO PCT/IL2004/000453 patent/WO2004106486A2/fr active Application Filing
- 2004-05-27 KR KR1020117003840A patent/KR101122160B1/ko not_active IP Right Cessation
- 2004-05-27 CN CN2004800212175A patent/CN1826122B/zh not_active Expired - Fee Related
-
2005
- 2005-07-19 US US11/183,884 patent/US7504388B2/en not_active Expired - Lifetime
- 2005-11-24 IL IL172165A patent/IL172165A/en active IP Right Grant
- 2005-11-28 KR KR1020057022741A patent/KR101081977B1/ko not_active IP Right Cessation
- 2005-12-07 ZA ZA200509929A patent/ZA200509929B/en unknown
-
2006
- 2006-08-03 HK HK06108608.1A patent/HK1088234A1/xx not_active IP Right Cessation
- 2006-09-28 US US11/528,657 patent/US7625882B2/en not_active Expired - Lifetime
-
2009
- 2009-02-17 US US12/371,930 patent/US7893291B2/en not_active Expired - Fee Related
- 2009-04-06 RU RU2009112686/04A patent/RU2482854C2/ru not_active IP Right Cessation
- 2009-10-14 US US12/588,371 patent/US7973023B2/en not_active Expired - Fee Related
-
2011
- 2011-01-06 US US12/985,365 patent/US8158611B2/en not_active Expired - Fee Related
- 2011-04-13 US US13/085,542 patent/US8501715B2/en not_active Expired - Lifetime
-
2012
- 2012-03-27 US US13/431,262 patent/US8563534B2/en not_active Expired - Lifetime
- 2012-11-27 JP JP2012258496A patent/JP2013079247A/ja active Pending
-
2013
- 2013-02-21 RU RU2013107800/04A patent/RU2013107800A/ru not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1088234A1 (en) | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | |
IL181706A0 (en) | The treatment of inflammatory disorders and pain | |
IL173129A0 (en) | 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | |
SI1446122T1 (sl) | Uporaba flibanserina pri zdravljenju motenj seksualne zelje | |
IL178758A0 (en) | Use of flibanserin in the treatment of premenstrual and other female sexual disorders | |
EP1489915A4 (fr) | Traitement et prevention de troubles inflammatoires | |
IL155092A0 (en) | Compounds useful in the treatment of inflammatory diseases | |
HK1089155A1 (en) | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | |
AU2003233583A8 (en) | Oral lactoferrin in the treatment of respiratory disorders | |
EP1450837A4 (fr) | Recepteurs de l'interleukine-1 dans le traitement de maladies | |
IL175610A0 (en) | Methods and reagents for the treatment of inflammatory disorders | |
EP1744740A4 (fr) | Derives d'acide phenoxyalkycarboxylique pour le traitement des maladies inflammatoires | |
AU2003228819A8 (en) | Combinations for the treatment of inflammatory skin disorders | |
PL1696947T3 (pl) | Zastosowanie erytropoetyny w leczeniu zaburzeń dystrybucji żelaza w przewlekłych chorobach zapalnych jelit | |
IL155174A0 (en) | Methods and compositions for the treatment of inflammatory diseases | |
PL366906A1 (en) | Imidazotriazinones derivatives and their use against inflammatory processes and/or immune diseases | |
AU2003244455A1 (en) | Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases | |
NO20054160D0 (no) | Imidazopyridin-inneholdende kombinasjoner og deres anvendelse i behandling av gastrointestinale inflammatoriske lidelser | |
GB0419828D0 (en) | The treatment of inflammatroy disorders and pain | |
AU2003244437A1 (en) | Quinoxalinones and their use especially in the treatment of cardiovascular diseases | |
AU2003217432A8 (en) | Angiopoietin-1 in the treatment of disease | |
GB0513413D0 (en) | The treatment of inflammatory disorders and pain | |
GB0423926D0 (en) | The treatment of Inflammatory disorders and pain | |
AU2002302618A1 (en) | 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases | |
ZA200509171B (en) | Hydroxamic acids useful in the treatment of hyperproliferative disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170527 |